The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).
 
Jennifer J. Wu
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst)
 
Emily Catherine Atkinson
No Relationships to Disclose
 
Lawrence P. Leichman
No Relationships to Disclose
 
Hitendra Patel
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)
 
Syma Iqbal
Honoraria - Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; Roche; Roche; Roche; Roche
Consulting or Advisory Role - Roche; Roche; Roche; Roche
Speakers' Bureau - Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai
Research Funding - Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Bayer/Onyx
Travel, Accommodations, Expenses - Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai
 
Kevin Lee Du
No Relationships to Disclose
 
Costas Bizekis
Consulting or Advisory Role - CSA Associates; CSA Associates; CSA Associates; CSA Associates
 
Judith D. Goldberg
No Relationships to Disclose
 
Charles R. Thomas
Employment - AMA; AMA; AMA; AMA
Consulting or Advisory Role - AMA; AMA; AMA; AMA
Travel, Accommodations, Expenses - Lilly; Lilly; Lilly; Lilly
 
Deirdre Jill Cohen
Consulting or Advisory Role - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)
 
Daniel Jacob Becker
No Relationships to Disclose
 
Despina Siolas
Consulting or Advisory Role - MedImmune; MedImmune
Patents, Royalties, Other Intellectual Property - Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory
Other Relationship - Medal Pharmaceuticals; Medal Pharmaceuticals
 
Nina Beri
No Relationships to Disclose
 
Paul Eliezer Oberstein
Consulting or Advisory Role - BTG; BTG; BTG; BTG; Celgene; Celgene; Celgene; Celgene; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck; Purdue Pharma; Purdue Pharma; Purdue Pharma; Purdue Pharma; TYME; TYME; TYME; TYME
Research Funding - Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck; Merck; Merck; Merck
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - Lilly; Lilly; Lilly; Lilly; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals
Research Funding - Arog (Inst); Arog (Inst); Arog (Inst); Arog (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Zymeworks; Zymeworks; Zymeworks; Zymeworks
Travel, Accommodations, Expenses - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals